ERM LIMITED
Company number 03128071 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment — ERM Limited (Company No. 03128071)
Important scope note: I've been asked to run a full diagnostic, but the data supplied is a corporate record extract, not a set of accounts. There is no profit and loss account, balance sheet, cash flow statement or notes in the pack. So this is best understood as a triage and preliminary examination — I can read the pulse and check the reflexes, but I cannot yet take blood pressure or run the bloods. Where a metric is unmeasurable, I say so rather than guessing.
1. Financial Health Score
Grade: B — Provisional ("Stable vitals, incomplete examination")
Why a B and not higher: Every observable vital sign is healthy. The company is active, has never entered liquidation, administration or receivership, has no overdue filings, has a full three-decade trading history, a professional governance structure and a solvent-sounding group parent. On the corporate record alone this would score an A.
Why not lower: There are no symptoms of distress at all — no insolvency events, no filing default, no governance vacuum, no director disqualification flags in the data.
Why the grade is capped: A financial health grade requires financial evidence. Because no accounts are present, profitability, liquidity, solvency and gearing are all unmeasured. A B is therefore the honest ceiling: the patient looks well, but the test results are missing.
2. Key Vital Signs
| Vital Sign | Reading | Interpretation |
|---|---|---|
| Corporate pulse (status) | Active; not in liquidation | Heartbeat present and regular. No insolvency events on record. |
| Respiration (filing compliance) | Accounts: last made up 31 Mar 2025, next due 31 Dec 2026, not overdue. Confirmation statement: last made up 20 Nov 2025, next due 4 Dec 2026, not overdue | Breathing unaided — no filing distress. One note: the next accounts date appears longer than the standard 9-month window after a 31 March year end (which would ordinarily be 31 December 2025). This may reflect an extended accounting reference period or a record quirk — worth verifying, but it is not currently a default. |
| Medical record depth (accounts category) | "Full" accounts | A rich diagnostic file exists. Full accounts (even filleted for a private company) will show balance sheet, and often the P&L and notes — this is the missing scan I would request first. |
| Blood supply (ownership) | Eagle 4 Limited owns >75% of shares and votes, with rights to appoint/remove directors | The company is a wholly-controlled subsidiary. Its financial circulation is inseparable from the parent's. This is a strength (access to group support) and a dependency (no independent life support). |
| Nervous system (governance) | 3 current directors, a sitting company secretary, 1 director resigned | Stable, professionally administered. A single resignation is normal churn, but a change at board level in a holding company is worth a glance for strategic signals. |
| Age / chronic history | Incorporated 20 Nov 1995; renamed from ERM-Europe (Holdings) Limited in 1999 | Thirty years of corporate life. Longevity is itself a health indicator — survivors rarely have fatal structural flaws. |
| Constitution (equity base) | Share capital £86,823.75 | Thin, but entirely normal for a head-office/holding entity. Do not read this as a weakness — in holding companies, equity strength sits in reserves, not issued capital. |
| Body type (business activity) | SIC 70100 — Activities of head offices | This is a skeletal/conduit entity: it holds investments in, and provides services to, operating subsidiaries. Its own balance sheet will be dominated by fixed asset investments and intercompany balances. Judging it on standalone trading metrics would be a misdiagnosis. |
| Operational substance | Group brand erm.com — global sustainability consultancy | The underlying business is a real, trading, international consultancy. Economic substance sits below this entity, not in it. |
Metrics I could not measure (and would need to): gross and net margin, EBITDA, net current assets (working capital), current and quick ratios, gearing, interest cover, net assets, P&L reserve trend, debtor and creditor ageing, intercompany balances, going-concern disclosure, and dividend flows to the parent.
3. Diagnosis
Primary finding: asymptomatic on all available evidence, with an incomplete diagnostic work-up.
Three things stand out.
First, compliance health is excellent. In UK company diagnostics, overdue accounts and confirmation statements are the earliest, most reliable fever symptoms of trouble — they typically precede cash strain, disputes and insolvency. This company shows none of them, across a 30-year history. That is a genuinely good sign, not a formality.
Second, this is a holding company, so the standard vital-sign panel doesn't apply cleanly. For an SIC 70100 entity, the meaningful questions are not "is it profitable?" but "are the subsidiaries performing?", "are intercompany balances recoverable?", "is the parent injecting or extracting cash?", and "is there a going-concern dependency on group support?" A head-office company can look perfectly healthy right up to the moment its subsidiary writes down an investment — the pathology shows up in the investment line, not the trading line.
Third, ownership concentration is the dominant risk factor. With a single corporate shareholder above 75%, the company's financial health is effectively a proxy for the group's. There is no minority interest to protect, no external covenant pressure visible, and full control by the parent. The practical consequence: dividends, intercompany funding and capital structure will be set by group treasury policy, not by this entity's own needs. That is normal for a group structure — but it means standalone analysis has limited predictive power.
What I would want to rule out (the differential diagnosis): an investment in subsidiaries carried above recoverable value; intercompany receivables that are effectively equity in disguise; a P&L reserve that is negative and quietly being rebuilt; and reliance on a parent support letter in the going-concern note.
4. Recommendations
Diagnostic (do these first): 1. Pull the full accounts to 31 March 2025 from the public register. As a "Full" filer, the balance sheet and notes should be available. That single document converts this from a B-provisional into a real grade. 2. Map the balance sheet shape — what proportion is fixed asset investments, what proportion is intercompany debtors, and what sits in creditors due within one year. For a head-office entity, that composition is the diagnosis. 3. Read the going-concern and principal-risks disclosures in the strategic/directors' report. Any mention of parent support, group facilities or covenant reliance tells you where the real oxygen comes from. 4. Check the P&L reserve trend over 3–5 years. A rising reserve means the group is retaining value here; a falling or negative reserve means this entity is absorbing losses or distributing aggressively.
Monitoring (ongoing health maintenance): 5. Track the filing calendar actively. The next confirmation statement (4 Dec 2026) and next accounts (31 Dec 2026) are both live obligations. Diarise them 60 days out — compliance slippage is the cheapest early-warning signal you will ever get. 6. Watch the board. One director resignation is unremarkable; a pattern of departures, or a change of company secretary, can signal group restructuring. Note also that the resignation date recorded (Oct 2026) is after the last accounts period end — confirm it has been properly notified. 7. Clarify the accounts due date anomaly with the filing agent, purely to avoid a surprise penalty.
Strategic: 8. Assess at group level, not entity level. Request consolidated figures for Eagle 4 Limited or the immediate group. ERM Limited's own numbers will tell you about capital structure; only the consolidated view tells you about financial health.
This assessment is based solely on the corporate record data supplied and is a diagnostic opinion for information purposes, not formal audit, tax or investment advice. It should be verified against the filed accounts before any decision is taken.